ArticleJournal of immunology (Baltimore, Md. : 1950)2013
Cutting edge: rapid boosting of cross-reactive memory CD8 T cells broadens the protective capacity of the Flumist vaccine.
Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- Trial
- Cross-reactive tissue-resident memory T lymphocytes-concepts, evidence, and open questions.Journal of translational medicine · 2026Review
- Review
- Vaccine Strategies to Elicit Mucosal Immunity.Vaccines · 2024Review
- Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens.PLoS pathogens · 2023Article
- Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals.International journal of molecular sciences · 2022Review
- Detrimental impact of allergic airway disease on live attenuated influenza vaccine.Health science reports · 2021Article
- Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges.NPJ vaccines · 2021Article
- Review
- Influenza-Specific Lung-Resident Memory CD8Cold Spring Harbor perspectives in biology · 2021Review
- Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine.Vaccines · 2020Review
- Article
- Lessons from next generation influenza vaccines for inflammatory disease therapies.International immunopharmacology · 2019Review
- Protective role for the N-terminal domain of α-dystroglycan in Influenza A virus proliferation.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Imprinting and Editing of the Human CD4 T Cell Response to Influenza Virus.Frontiers in immunology · 2019Article
- Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.Drugs · 2018Review
- The Respiratory Environment Diverts the Development of Antiviral Memory CD8 T Cells.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine.Vaccines · 2018Review
- Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 viruses.Scientific reports · 2017Article
- Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Memory CD8 T cells recognizing conserved proteins from influenza A virus (IAV), such as nucleoprotein, have the potential to provide protection in individuals who lack the proper neutralizing Abs. In this study, we show that the most potent CD8 T cell-inducing influenza vaccine on the market (Flumist) does not induce sufficient numbers of cross-reactive CD8 T cells to provide substantial protection against lethal nonhomologous IAV challenge. However, Flumist-primed CD8 T cells rapidly acquire memory characteristics and can respond to short-interval boosting to greatly enlarge the IAV-specific memory pool, which is sufficient to protect mice from nonhomologous IAV challenge. Thus, a current vaccine strategy, Flumist, may serve as a priming platform for the rapid induction of large numbers of memory CD8 T cells with the capacity for broad protection against influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.